BGNE vs. VTRS, KRTX, TEVA, RDY, UTHR, SRPT, CTLT, BMRN, ROIV, and LEGN
Should you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include Viatris (VTRS), Karuna Therapeutics (KRTX), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Catalent (CTLT), BioMarin Pharmaceutical (BMRN), Roivant Sciences (ROIV), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
BeiGene (NASDAQ:BGNE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
BeiGene received 518 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.10% of users gave BeiGene an outperform vote while only 35.59% of users gave Viatris an outperform vote.
48.5% of BeiGene shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 7.4% of BeiGene shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Viatris has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
Viatris has a net margin of 0.35% compared to BeiGene's net margin of -35.86%. Viatris' return on equity of 17.03% beat BeiGene's return on equity.
BeiGene has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
BeiGene currently has a consensus target price of $250.13, suggesting a potential upside of 73.56%. Viatris has a consensus target price of $11.00, suggesting a potential downside of 4.76%. Given BeiGene's stronger consensus rating and higher probable upside, equities analysts clearly believe BeiGene is more favorable than Viatris.
In the previous week, BeiGene had 10 more articles in the media than Viatris. MarketBeat recorded 11 mentions for BeiGene and 1 mentions for Viatris. Viatris' average media sentiment score of 1.20 beat BeiGene's score of 0.36 indicating that Viatris is being referred to more favorably in the news media.
Summary
Viatris beats BeiGene on 10 of the 18 factors compared between the two stocks.
Get BeiGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
